Douglas J. Swirsky Sells 6,939 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) CFO Douglas J. Swirsky sold 6,939 shares of MaxCyte stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $3.18, for a total value of $22,066.02. Following the transaction, the chief financial officer now owns 111,811 shares of the company’s stock, valued at $355,558.98. The trade was a 5.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

MaxCyte Trading Up 0.7 %

Shares of NASDAQ:MXCT opened at $3.09 on Friday. MaxCyte, Inc. has a 12-month low of $2.76 and a 12-month high of $5.26. The stock has a fifty day simple moving average of $4.04 and a two-hundred day simple moving average of $3.93. The stock has a market capitalization of $327.63 million, a price-to-earnings ratio of -9.09 and a beta of 1.35.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MXCT. Royce & Associates LP raised its stake in shares of MaxCyte by 59.8% in the third quarter. Royce & Associates LP now owns 323,924 shares of the company’s stock worth $1,260,000 after purchasing an additional 121,272 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of MaxCyte in the third quarter worth $51,000. Mudita Advisors LLP raised its stake in shares of MaxCyte by 5.6% in the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock worth $12,267,000 after purchasing an additional 167,101 shares during the last quarter. Verition Fund Management LLC raised its stake in shares of MaxCyte by 39.5% in the third quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after purchasing an additional 6,045 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its stake in shares of MaxCyte by 13.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock worth $5,426,000 after purchasing an additional 169,250 shares during the last quarter. Hedge funds and other institutional investors own 68.81% of the company’s stock.

Wall Street Analysts Forecast Growth

MXCT has been the subject of a number of recent research reports. BTIG Research set a $6.00 price objective on MaxCyte and gave the company a “buy” rating in a research note on Wednesday, March 12th. Stifel Nicolaus lowered their price objective on MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.